Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
United States Paola Bonvicini Yuji Kawahara Taiho Pharmaceutical Co Ltd Helsinn Birex Pharmaceuticals Ltd Strategic Communications
Source: apnews.com